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Introduction: Neuropsychiatric manifestation in systemic lupus erythematosus (NPSLE) is one of the most serious
complications of the disease. Previous studies revealed the strong association between serum anti-Sm and organic
brain syndrome, consisting mainly of acute confusional state (ACS) of diffuse psychiatric/neuropsychological syndromes
(diffuse NPSLE). However, the precise mechanism by which anti-Sm causes diffuse NPSLE remains unclear. Of note,
recent studies demonstrated that anti-U1 RNP antibodies (anti-RNP) in cerebrospinal fluid (CSF) are associated with
NPSLE. The present study was designed to explore the association of anti-Sm antibodies in CSF with NPSLE.
Methods: Paired serum and CSF specimens were obtained from 72 patients with NPSLE (49 with diffuse NPSLE, 23
with neurological syndromes or peripheral neuropathy (focal NPSLE) and from 22 control patients with non-SLE
neurological diseases. Sera were also obtained from 41 patients with active SLE without neuropsychiatric manifestations
(non-NPSLE). Anti-Sm and anti-RNP were measured by enzyme-linked immunosorbent assay (ELISA). Blood-brain
barrier (BBB) function and intrathecal anti-Sm production were evaluated by Q albumin and CSF anti-Sm index,
respectively. Binding of anti-Sm to neuroblastoma cell lines SK-N-MC and Neuro2a was examined by flow
cytometry and by cell ELISA.
Results: Anti-Sm and anti-RNP in CSF and sera were elevated in NPSLE compared with non-SLE control. CSF
anti-Sm, but not CSF anti-RNP, was significantly elevated in ACS compared with non-ACS diffuse NPSLE or with
focal NPSLE. By contrast, there were no significant differences in serum anti-Sm or anti-RNP among subsets of
NPSLE and non-NPSLE. Whereas there were no significant differences in CSF anti-Sm index, Q albumin was
elevated in ACS compared with non-ACS or with focal NPSLE. Notably, CSF anti-Sm was correlated with Q albumin
(r = 0.2373, P = 0.0447) or with serum anti-Sm (r = 0.7185, P <0.0001) in 72 patients with NPSLE. Finally, monoclonal
anti-Sm and purified human anti-Sm bound to the surface of SK-N-MC and Neuro2a.
Conclusions: These results demonstrate that the elevation of CSF anti-Sm through transudation from systemic
circulation due to damaged BBB plays a critical role in the pathogenesis of ACS. More importantly, the data
indicate that anti-Sm is yet another autoantibody with presumed neural toxicity, but might not be the last.Introduction
Neuropsychiatric manifestation in systemic lupus erythe-
matosus (NPSLE) is one of the most serious complications
of the disease [1,2]. The role of anti-neuronal antibodies in
the pathogenesis of NPSLE has been appreciated since
Bluestein et al. demonstrated that immunoglobulin G (IgG)
anti-neuronal antibodies were present in much higher* Correspondence: shunsei_tenpoint@yahoo.co.jp
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stated.concentrations in the cerebrospinal fluid (CSF) from pa-
tients with active NPSLE [3]. Of interest, CSF IgG anti-
neuronal antibodies were found to be significantly elevated
in patients with diffuse psychiatric/neuropsychological syn-
dromes (diffuse NPSLE) compared with neurologic syn-
dromes (focal NPSLE) [4]. However, the epitopes to which
CSF anti-neuronal antibodies were directed have not been
fully delineated.
N-methyl-D-aspartate (NMDA) receptors are one of
the glutamate receptor families and its stimulation has
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Diffuse NPSLE 49 7/42 38.3 ± 14.4















Non SLE control 22 21/1 49.4 ± 10.5
*Two patients also presented with mood disorder. SD: standard deviation; (NP)
SLE: (neuropsychiatric) systemic lupus erythematosus.
Hirohata et al. Arthritis Research & Therapy 2014, 16:450 Page 2 of 9
http://arthritis-research.com/content/16/1/450the central nervous system (CNS) [5]. DeGiorgio et al.
demonstrated that a subset of murine anti-DNA anti-
bodies cross-reacts with a sequence within the NMDA
receptor subunit NR2 [6]. Furthermore, injection into
mouse brain of such cross-reactive anti-DNA antibodies
purified from serum or CSF of an SLE patient with pro-
gressive cognitive impairment caused neuronal damage
[6]. Notably, the presence of such cross-reactive anti-
DNA antibodies in the serum compartment alone could
not result in brain damage, which also requires a break-
down of the blood-brain barrier (BBB) to allow such auto-
antibodies to enter the CNS [7]. Accordingly, we showed
that CSF anti-NMDA receptor subunit NR2 (anti-NR2)
antibodies, but not serum anti-NR2, were closely associ-
ated with diffuse NPSLE [8].
On the other hand, the association of serum anti-Sm
antibodies with CNS involvement in SLE has been sug-
gested [9,10]. In addition, a strong association was found
between serum anti-Sm and organic brain syndrome,
consisting mainly of acute confusional state (ACS) of dif-
fuse NPSLE [11]. However, the precise mechanism by
which anti-Sm causes diffuse NPSLE remains unclear.
Of note, recent studies have demonstrated that anti-U1
RNP antibodies (anti-RNP) in CSF, but not those in
serum, are associated with central neuropsychiatric man-
ifestations in SLE and mixed connected tissue disease
(MCTD) [12]. It should be pointed out that anti-Sm and
anti-RNP are closely correlated. Thus, the antibody pat-
tern produced by the mice immunized with exogenous
U1 small nuclear RNP particles was strikingly similar to
that observed in patients with SLE [13]. It is therefore
possible that anti-Sm might also be present in CSF from
patients with NPSLE. The current studies were therefore
undertaken to compare the levels of CSF anti-Sm in pa-




Seventy-two patients with SLE were included in the
present study. All patients fulfilled the American College
of Rheumatology (ACR) 1982 revised criteria for the clas-
sification of SLE [14]. Of the 72 NPSLE patients, 49
showed diffuse psychiatric/neuropsychological syndromes
(diffuse NPSLE) according to the 1999 ACR definition of
NPSLE [15], whereas 23 patients showed CNS manifesta-
tions other than diffuse NPSLE, including neurologic
syndromes and peripheral nervous system involvements
(focal NPSLE) (Table 1). All the patients with NPSLE were
hospitalized in Teikyo University Hospital or other corre-
lated hospitals between 2000 and 2008. In addition, serum
samples were obtained from 41 patients with active SLE
without neuropsychiatric manifestations (non-NPSLE)
(age 36.9 ± 14.9 years (mean ± standard deviation (SD))).As non-SLE control, 22 patients with non-SLE non-
inflammatory neurologic diseases (7 with cervical
spondylitis, 7 with cerebrovascular diseases, 3 with
neurodegenerative diseases, 2 with hyperventilation
syndrome, 2 with diabetic neuropathy, 1 with head-
ache) were studied. All the 135 patients gave informed
consent. This study was approved by the institutional
ethics committee of Teikyo University School of
Medicine.
CSF specimens were obtained from the patients by
lumbar puncture on the same day serum samples were
obtained, when neurologists and rheumatologists made
the diagnosis of NPSLE in each institution. These sam-
ples were kept frozen at −30°C until they were assayed.
All assays were performed without knowledge of the
diagnosis or clinical presentation. Furthermore, upon en-
tering the present study, the diagnosis of the 72 patients
with NPSLE and its classification was reconfirmed by re-
ferral to rheumatologists in charge as well as by review
of hospital case records in each institution.
Measurement of ant-Sm, anti-RNP, anti-NMDA receptor
subunit NR2 (anti-NR2) and albumin
Anti-Sm and anti-RNP levels in CSF and sera were mea-
sured using enzyme-linked immunosorbent assay (ELISA)
kits, MESACUP™-3 test Sm and MESACUP™-2 test RNP
(MBL, Nagano, Japan). Arbitrary unit was designated
according to the manufacturer’s instructions. Anti-NR2
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the highly purified synthetic 10 amino-acid peptide
DWEYSVWLSN [6], conjugated to human serum al-
bumin (HSA) as previously described [8]. Albumin
levels in CSF and sera were measured by ELISA using
the Human Albumin ELISA Quantitation Set (Bethyl
Laboratories, Montgomery, TX, USA).
Evaluation of blood-brain barrier function and intrathecal
synthesis of anti-Sm or anti-RNP
Blood-brain barrier (BBB) function and intrathecal syn-
thesis of anti-Sm or anti-RNP were evaluated by Q albu-
min (CSF albumin × 1,000/serum albumin) and by CSF
anti-Sm or anti-RNP index ([CSF anti-Sm or anti-RNP ×
serum albumin]/[serum anti-Sm or anti-RNP × CSF al-
bumin]), respectively, as previously described [16].
Immunofluorescence staining and analysis
To explore whether anti-Sm binds neuronal cells, the
binding of murine monoclonal anti-Sm (murine IgG3,
Abcam, Tokyo, Japan) to human neuroblastoma cell
line SK-N-MC cells and murine neuroblastoma cell line
Neuro2a cells was examined. Briefly, after being fixed with
1% paraformaldehyde in phosphate-buffered saline (PBS)
(pH 7.2) for 5 minutes at 37°C, the cells were washed with
2% normal human serum in PBS and 0.1% sodium azide
(staining buffer). The cells were then reacted with
monoclonal anti-Sm or control murine IgG3 (Abcam)
(5 μg /ml) at 4°C for 30 minutes. After 3 washes with
staining buffer, the cells were counterstained with fluores-
cein isothiocyanate-conjugated F(ab’)2 fragments of goat
anti-mouse IgG (Cappel Laboratories, Cochranville, PA,
USA). After staining, the cells were treated in saline with
50 μg/ml propidium iodide (PI; Sigma-Aldrich, St. Louis,
MO, USA) for more than 5 minutes at room temperature,
followed by analysis using Cell Lab Quanta SC (Beckman
Coulter, Miami, FL, USA). The gating threshold for PI
staining to identify viable cells was determined using cells
without PI staining [17]. The percentages of cells that
were stained positively for anti-Sm were determined in re-
lation to the percentage of staining with control murine
IgG3. The density of staining was expressed as the change
in mean fluorescence intensity (MFI) for staining with
anti-Sm, which was calculated by subtracting the MFI of
staining with control IgG3.
Cell ELISA
To further confirm the binding of anti-Sm to neuronal
cells, a cell ELISA was carried out using human neuroblast-
oma cell line SK-N-MC as previously described [4]. Briefly,
SK-N-MC cells were seeded at a density of 5 × 104 per well
in wells of a flat-bottomed 96-well tissue culture plate for
48 hours, after which the cells were fixed with 1% parafor-
maldehyde in PBS for 5 minutes at 37°C. After 3 washeswith PBS containing 0.05% Tween 20, the wells were
reacted with 50 μl of murine monoclonal anti-Sm (5 μg/ml)
or human anti-Sm (50 μg/ml) purified from IgG fraction of
serum of an SLE patient using an N-hydroxysuccinimide-
activated Sepharose HP column (Amersham Biosciences,
Uppsala, Sweden) coupled with purified human Sm anti-
gens (ImmunoVision, Springdale, AR, USA) according to
the manufacturer’s instructions. Murine monoclonal IgG3
(5 μg/ml) or control human IgG (50 μg/ml) purified from
serum of a normal healthy individual was used as con-
trol. After incubation for 1 hour at 37°C, bound IgG was
detected with peroxidase-conjugated F(ab’)2 fragments
of goat anti-mouse IgG or anti-human IgG (Cappel
Laboratories, West Chester, PA, USA), as previously de-
scribed [4]. The results are expressed by the absorbance
at 492 nm (OD492).
Statistical analysis
Comparisons among 3 groups and those between 2 groups
were carried out by Kruskal-Wallis test with Dunn’s
multiple comparison test and by Mann-Whitney’s U test,
respectively, using GraphPad Prism 4 (Windows ver. 4.03;
GraphPad Software, Inc., San Diego, CA, USA).
Results
CSF anti-Sm and anti-RNP in NPSLE
Anti-Sm and anti-RNP in CSF were determined by
ELISA. Anti-Sm and anti-RNP in CSF from 22 control
patients were 0.009 ± 0.029 U/ml and 0.007 ± 0.007 U/ml
(mean ± SD), respectively. Both anti-Sm and anti-RNP in
CSF were significantly elevated in NPSLE compared with
non-SLE control. Among subsets of NPSLE, CSF anti-Sm
was significantly elevated in ACS compared with non-
ACS diffuse NPSLE (P = 0.0028) or with focal NPSLE
(P = 0.0008) (Figure 1). By contrast, there were no signifi-
cant differences in CSF anti-RNP among the 3 groups of
NPSLE. These results indicate that the elevation of CSF
anti-Sm, but not that of anti-RNP, is associated with the
development of ACS.
Serum anti-Sm and anti-RNP in NPSLE
We next examined anti-Sm and anti-RNP in sera. Anti-
Sm and anti-RNP in sera from 22 control patients were
1.221 ± 0.644 U/ml and 3.704 ± 2.855 U/ml (mean ± SD),
respectively. Both anti-Sm and anti-RNP in sera were
significantly elevated in NPSLE as well as in non-NPSLE
compared with non-SLE control, whereas there were no
significant differences between NPSLE and non-NPSLE.
Accordingly, there were no significant differences in anti-
Sm and anti-RNP in the sera among subsets of NPSLE
and non-NPSLE. Although serum anti-Sm appeared to be
higher in ACS than in the other 3 groups of SLE, it did
not reach statistical significance (Figure 2). These results
Figure 1 Cerebrospinal fluid (CSF) anti-Sm and anti-RNP in NPSLE. CSF anti-Sm levels were 0.009 ± 0.029 (mean ± SD) in non-SLE neurological
control and 0.977 ± 2.221 in NPSLE: 2.604 ± 3.774 in acute confusional state (ACS), 0.528 ± 0.897 in non-ACS diffuse NPSLE, 0.219 ± 0.205 in focal
NPSLE. CSF anti-RNP levels were 0.007 ± 0.007 (mean ± SD) in non-SLE neurological control and 2.164 ± 3.984 in NPSLE: 2.506 ± 2.967 in ACS,
3.010 ± 5.431 in non-ACS diffuse NPSLE, 0.778 ± 1.437 in focal NPSLE. Horizontal lines indicate median. NPSLE: neuropsychiatric systemic lupus
erythematosus; SD: standard deviation.
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ute only little, if any, to the development of ACS.
Intrathecal production of anti-Sm and anti-RNP in NPSLE
Previous studies demonstrated that intrathecal immuno-
globulin production was increased in NPSLE [18,19]. It
is therefore possible that intrathecal production of ant-
Sm and anti-RNP might be increased in NPSLE. We
next examined CSF anti-Sm or anti-RNP index, which
reflects the intrathecal production of these antibodies.
CSF anti-Sm and anti-RNP indices in 22 control patients
were 0.881 ± 1.696 and 0.941 ± 1.347 (mean ± SD), re-
spectively. Both CSF anti-Sm and anti-RNP indices were
significantly elevated in NPSLE compared with non-SLE
control. However, there were no significant differences
in CSF anti-Sm or anti-RNP index among the 3 groups of
NPSLE (Figure 3). These results indicate that the elevation
of CSF anti-Sm in ACS cannot be accounted for by the
increased production within the CNS.
Relationship of BBB integrity and serum anti-Sm with CSF
anti-Sm in NPSLE
It has been well appreciated that damages in the BBB re-
sult in the elevation of CSF immunoglobulin [16,18,19].
We next examined Q albumin, which reflects the BBB
integrity. Q albumin values in 22 control patients were
2.84 ± 1.29 (mean ± SD). Notably, there were no signifi-
cant differences in Q albumin in NPSLE compared withthe control group. However, among subsets of NPSLE, Q
albumin was significantly elevated in ACS compared with
non-ACS diffuse NPSLE (P = 0.0017) or with focal NPSLE
(P = 0.0089), and also with non-SLE control (P = 0.0024)
(Figure 4, upper panels). Accordingly, CSF anti-Sm was sig-
nificantly correlated with Q albumin in NPSLE (r = 0.2373,
P = 0.0477), although the correlation was not strong. CSF
anti-Sm was also correlated with serum anti-Sm in NPSLE
(r = 0.7185, P <0.0001) (Figure 4, lower panels). These re-
sults therefore indicate that the elevation of CSF anti-Sm
in ACS is mainly a result of transudation of anti-Sm from
the systemic circulation due to damaged BBB.Relationship of CSF anti-NR2 with CSF anti-Sm in NPSLE
We have recently demonstrated that CSF anti-NR2 levels
and Q albumin were significantly higher in ACS than in
non-ACS diffuse NPSLE, indicating that the severity of
BBB damage results in the elevation of CSF anti-NR2
[20]. We next compared CSF anti-Sm with CSF anti-
NR2 in patients with NPSLE. As shown in Figure 5, CSF
anti-Sm was significantly correlated with CSF anti-NR2
(r = 0.2745, P = 0.0196) in 72 patients with NPSLE. By con-
trast, there was no significant correlation between serum
anti-Sm and serum anti-NR2 (r = 0.0445, P = 0.7103)
(Figure 5 lower panel). It is thus most likely that the posi-
tive correlation between CSF anti-Sm and anti-NR2 might
be due to the BBB damage. Moreover, the data suggest that
Figure 2 Serum anti-Sm and anti-RNP in NPSLE. Serum anti-Sm levels were 1.221 ± 0.644 (mean ± SD) in non-SLE neurological control, 49.94 ±
75.04 in NPSLE and 35.76 ± 45.41 in non-NPSLE: 96.39 ± 116.4 in acute confusional state (ACS), 35.61 ± 47.1 in non-ACS diffuse NPSLE, 30.24 ± 40.22
in focal NPSLE. Serum anti-RNP levels were 3.704 ± 2.855 (mean ± SD) in non-SLE neurological control, 80.05 ± 97.82 in NPSLE and 59.55 ± 67.37 in
non-NPSLE: 94.79 ± 117.7 in ACS, 92.41 ± 103.4 in non-ACS diffuse NPSLE, 51.76 ± 64.91 in focal NPSLE. Horizontal lines indicate median. NPSLE:
neuropsychiatric systemic lupus erythematosus; SD: standard deviation.
Figure 3 Intrathecal production of anti-Sm and anti-RNP in NPSLE. Cerebrospinal fluid (CSF) anti-Sm index was 0.881 ± 1.696 (mean ± SD) in
non-SLE neurological control and 35.14 ± 152.3 in NPSLE: 16.72 ± 37.61 in acute confusional state (ACS), 13.21 ± 23.35 in non-ACS diffuse NPSLE,
78.95 ± 264.5 in focal NPSLE. CSF anti-RNP index was 0.941 ± 1.347 (mean ± SD) in non-SLE neurological control and 12.10 ± 33.35 in NPSLE:
5.02 ± 7.89 in ACS, 14.35 ± 28.28 in non-ACS diffuse NPSLE, 15.00 ± 49.25 in focal NPSLE. Horizontal lines indicate median. NPSLE: neuropsychiatric
systemic lupus erythematosus; SD: standard deviation.
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Figure 4 Relationship of blood-brain barrier integrity and serum anti-Sm with cerebrospinal fluid (CSF) anti-Sm in NPSLE. In upper
panels, Q albumin values were 2.84 ± 1.29 (mean ± SD) in non-SLE neurological control and 6.05 ± 8.56 in NPSLE: 12.48 ± 13.80 in acute
confusional state (ACS), 4.14 ± 4.20 in non-ACS diffuse NPSLE, 3.22 ± 2.94 in focal NPSLE. Horizontal lines indicate median. In lower panels,
correlation between CSF anti-Sm and Q albumin and that between CSF anti-Sm and serum anti-Sm were evaluated by Spearman’s rank
correlation test. NPSLE: neuropsychiatric systemic lupus erythematosus; SD: standard deviation.
Figure 5 Relationship of anti-Sm with anti-NR2 in NPSLE. In upper
panels, correlation between cerebrospinal fluid (CSF) anti-NR2 and CSF
anti-Sm was evaluated. In lower panels, correlation between serum
anti-NR2 and serum anti-Sm was evaluated. Statistical analysis was
carried out by Spearman’s rank correlation test. NPSLE: neuropsychiatric
systemic lupus erythematosus.
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crucial for the development of ACS.Binding of ant-Sm with neuronal cells
The mechanism of anti-Sm to cause CNS damage is un-
known. One possibility is that anti-Sm might directly bind
neuronal cells and affect their functions. Final experiments
were therefore carried out to explore whether anti-Sm
might bind neuronal cells. As shown in Figure 6A, murine
monoclonal anti-Sm bound to paraformaldehyde-fixed
SK-N-MC cells and Neuro2a cells. Moreover, the data
of cell ELISA also demonstrate that purified human
anti-Sm as well as murine monoclonal anti-Sm bound
to paraformaldehyde-fixed SK-N-MC cells (Figure 6B).
The results therefore confirm that the epitopes recog-
nized by anti-Sm exist on the surface of neuronal cells.Discussion
This study is the first to show the clinical significance of
CSF anti-Sm. Thus, the results in the present study have
disclosed that CSF anti-Sm is elevated in ACS, a severe
form of diffuse NPSLE. By contrast, there were no signifi-
cant differences in CSF anti-RNP among various subtypes
of NPSLE, although both CSF anti-Sm and anti-RNP were
increased in NPSLE compared with non-SLE control. It
has been pointed out that anti-Sm might be involved in
the pathogenesis of NPSLE [9,10]. Especially, serum
anti-Sm was associated with organic brain syndrome,
consisting mainly of ACS of diffuse NPSLE [11]. Con-
sistently, serum anti-Sm appeared to be elevated in ACS
Figure 6 Binding of anti-Sm to neuronal cells. (A) After fixation with 1% paraformaldehyde, SK-M-NC cells and Neuro2a cells were reacted with
murine monoclonal anti-Sm or control murine immunoglobulin G (IgG3) (5 μg/ml), followed by counterstaining with fluorescein isothiocyanate
(FITC)-conjugated goat F(ab’)2 anti-mouse IgG and with propidium iodide (PI). The cells were then analyzed by flow cytometry. Representative
FITC stainings on viable cells gated by negative staining with PI are shown. The percent positive as well as the mean fluorescence intensity (MFI)
for specific anti-Sm staining are indicated. (B) SK-N-MC cells were seeded in wells of a flat-bottomed 96-well culture plate. After fixation with 1%
paraformaldehyde, the wells were reacted with murine monoclonal anti-Sm (5 μg/ml) or human anti-Sm (50 μg/ml) purified from serum IgG
fraction of an SLE patient. Murine monoclonal IgG3 (5 μg/ml) or control human IgG (50 μg/ml) of a normal healthy individual was used as
controls. Bound IgG was detected with peroxidase-conjugated F(ab’)2 fragments of goat anti-mouse IgG or anti-human IgG. The results are
expressed by the absorbance at 492 nm (OD492). Error bars indicate standard deviation (SD) of triplicate determinations.
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significance.
Previous studies demonstrated that CSF anti-RNP was
associated with NPSLE and CNS manifestations in MCTD
[12]. However, the elevation of CSF anti-RNP was not spe-
cific in ACS or diffuse NPSLE, since CSF anti-RNP was also
elevated in patients with neurologic syndromes, including
aseptic meningitis, headache, demyelinating disorder or
movement disorder [12]. Accordingly, in the present study,
CSF anti-RNP was also elevated in focal NPSLE compar-
ably to diffuse NPSLE, confirming the observation in the
previous studies [12]. How anti-RNP is involved in the de-
velopment of NPSLE is currently unknown. Although the
possibility of induction of proinflammatory cytokines by
anti-RNP was suggested [12], further studies are required
to confirm this point.
Autoantibodies to NMDA receptors, a subgroup of the
glutamate receptor family, have recently attracted in-
creasing attention [5-7,21,22]. Thus, DeGiorgio et al.
showed that injection of anti-NR2 glutamate receptor
binding antibodies (purified antibodies from the sera or
CSF from NPSLE patients) into mice brain resulted in
apoptosis of the neuronal cells without signs of inflam-
mation [6]. Of note, Kowal et al. have demonstrated that
mice induced to express anti-NR2 in systemic circula-
tion have no neuronal damage unless breakdown of the
BBB takes place [7]. Importantly, we have demonstrated
that monoclonal anti-Sm binds to the surface of SK-N-
MC cells and Neuro2a cells, indicating that anti-Smreacts with neurons. Moreover, the presence of greater
amounts of anti-Sm in CSF was associated with ACS in
the present study. Notably, the effect of anti-NR2 anti-
bodies on neurons has been shown to be dose dependent
[22]. Thus, at low concentrations they alter synaptic func-
tion, whereas at higher concentrations they can cause
neuronal cell death by apoptosis [22]. It is therefore sug-
gested that the presence of higher concentrations of anti-
Sm within the CNS might cause more extensive neuronal
damage, resulting in the development of ACS. The influ-
ences of anti-Sm on the function and survival of neurons
are currently undetermined and need to be explored in
further studies.
It has been well recognized that intrathecal production
of immunoglobulin is increased in NPSLE irrespective of
focal NPSLE or diffuse NPSLE [18,19]. Notably, previous
studies revealed that CSF anti-RNP index was elevated
in NPSLE [12]. In the present study, CSF anti-RNP index
as well as CSF anti-Sm index was elevated in NPSLE com-
pared with non-SLE control. However, there were no sig-
nificant differences in CSF anti-Sm or anti-RNP index
among various subsets of NPSLE. Therefore, the elevations
of CSF anti-Sm levels in ACS compared with non-ACS dif-
fuse NPSLE or with focal NPSLE cannot be accounted for
by the increased intrathecal synthesis of anti-Sm.
BBB dysfunction results in the elevation of CSF im-
munoglobulin through the increased transudation from
the systemic circulation into the CNS. In the present
study, Q albumin values were not significantly elevated
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with the previous studies [18,19]. However, among vari-
ous types of NPSLE, Q albumin was significantly ele-
vated in ACS compared with non-ACS diffuse NPSLE or
with focal NPSLE in the present study, as is consistent
with our recent studies [20]. On the other hand, CSF
anti-Sm was significantly correlated with Q albumin, and
more closely with serum anti-Sm. However, there were
no significant differences in serum anti-Sm among vari-
ous subsets of NPSLE and non-NPSLE, although it ap-
peared to be higher in ACS. Taken together, these data
indicate that the damage in BBB rather than the eleva-
tion of serum anti-Sm is more crucial for the elevation
of CSF anti-Sm in ACS.
We have recently demonstrated that CSF anti-NR2
levels and Q albumin were significantly higher in ACS
than in non-ACS diffuse NPSLE, indicating that the se-
verity of BBB damage plays a crucial role in the develop-
ment of ACS through the accelerated entry of larger
amounts of anti-NR2 into the CNS [20]. The data in the
present study have further disclosed that the elevation of
CSF anti-Sm due to the damaged BBB is also involved in
the development of ACS. In addition, CSF anti-Sm was
significantly correlated with CSF anti-NR2 in NPSLE in
the present study. Since there was no significant correl-
ation between serum anti-Sm and anti-NR2, the positive
correlation between CSF anti-Sm and anti-NR2 might be
due to the BBB damage. More importantly, the data in
the present study indicate that the elevation of both
anti-Sm and anti-NR2 in CSF plays a crucial role in the
development of ACS. Further studies to explore the effects
of coexistence of anti-Sm and anti-NR2 on neuronal cells
would be important to delineate the precise mechanism
for the development of ACS.
The mechanism of damage in BBB in ACS has not
been determined at present. In this regard, it is likely
that several autoantibodies, such as anti-ribosomal P
protein antibodies and anti-NR2 antibodies, might result
in BBB damage, since they react with endothelial cells
[23-25]. Notably, recent studies have disclosed that an
anti-Sm autoantibody synergized with hemoglobin to en-
hance the secretion of proinflammatory cytokines while
eliciting the increased production of monocyte migratory
signals from endothelial cells [26]. It is therefore also
possible that anti-Sm also might result in BBB damage.
Further studies are required to explore the roles of a var-
iety of autoantibodies in BBB damage.
In the present study, there were no differences in CSF
anti-Sm or CSF anti-RNP between non-ACS diffuse
NPSLE and focal NPSLE. Since a number of autoanti-
bodies have been reported to be reactive to neurons,
including anti-ribosomal P protein antibodies [27], anti-
Ro antibodies [28], some anti-cardiolipin antibodies [29]
and anti-NR2 antibodies [6-8], it is possible that thepatterns of expression of several antibodies or their com-
bination in CSF might be different between non-ACS dif-
fuse NPSLE and focal NPSLE. Moreover, it is also possible
that anti-ribosomal P protein antibodies, anti-Ro anti-
bodies and some anti-cardiolipin antibodies might be also
involved in the development of ACS in combination with
anti-Sm and anti-NR2. Further studies are required to de-
lineate the whole spectrum of neuron-reactive autoanti-
bodies in CSF in order to understand the variability of
manifestations of NPSLE.
A limitation of our study is that it is cross-sectional
and the observations are associations and not fully causal,
though the binding of anti-Sm to neuroblastoma cell lines
suggests plausibility. Another limitation is the possibility
that anti-Sm might have preferential properties to pene-
trate the CNS, leading to its higher CSF levels just as a re-
flection of the peripheral milieu. Therefore, it would be
ideal to have an additional control of SLE patients with
anti-Sm and anti-RNP in sera without CNS symptoms
and study CSF anti-Sm and anti-RNP in such patients. In
this regard, 5 of the 23 patients with focal NPSLE showed
elevation of serum anti-Sm over 50.0 U/ml without psy-
chiatric manifestations. When compared with 5 patients
with ACS diffuse NPSLE who showed almost the same
values for serum anti-Sm, the 5 patients with focal
NPSLE showed significantly lower CSF anti-Sm values
(data not shown). Therefore, it is strongly suggested
that elevation of CSF anti-Sm might be causal for ACS
diffuse NPSLE.Conclusions
The current studies disclosed that CSF anti-Sm levels and
Q albumin were significantly higher in ACS than in non-
ACS diffuse NPSLE (anxiety disorder, cognitive dysfunc-
tion, mood disorder and psychosis) or in focal NPSLE,
whereas there was no significant difference in CSF anti-
Sm index among the 3 groups. CSF anti-Sm was signifi-
cantly correlated with Q albumin and with CSF anti-NR2
in NPSLE. Finally, anti-Sm has been demonstrated to react
with neuroblastoma cell lines. These results indicate that
the elevation of CSF anti-Sm and anti-NR2 due to BBB
damage plays a critical role in the pathogenesis of ACS, a
severe form of diffuse NPSLE. More importantly, the data
indicate that anti-Sm is yet another autoantibody with
presumed neural toxicity, but might not be the last.Abbreviations
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